Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  PledPharma AB (publ)    PLED   SE0003815604

PLEDPHARMA AB (PUBL) (PLED)
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

PledPharma publ : The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 01:46pm CEST


The data safety monitoring committee gave the approval to initiate the next cohort in the open-label, randomised, rising dose design, proof-of-principle safety and tolerability study with Aladote in patients treated with NAC for paracetamol overdose.       

The study is conducted at the University of Edinburgh, Queen’s Medical Research Institute in Scotland and will involve a total of 24 patients assigned into one of 3 dosing cohorts of 8 patients.

The first cohort receiving the lowest dose of the study drug has been completed and after reviewing the safety data the monitoring committee, in a meeting held on September 13, approved to continue with recruitment for the middle dose group.

 

For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62
[email protected]

Michaela Gertz, CFO, phone: +46 709 26 17 75
[email protected]

About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued development. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see www.pledpharma.se

 

Copyright © 2017 OMX AB (publ), source OMX

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PLEDPHARMA AB (PUBL)
05/14PLEDPHARMA PUBL : has completed the recruitment for the clinical trial with Alad..
AQ
04/03PLEDPHARMA PUBL : receives European approval of the composition of matter patent..
AQ
03/28PLEDPHARMA RECEIVES EUROPEAN APPROVA : PledPharma AB has received an approval* l..
AQ
02/23PLEDPHARMA AB : - Year-end Report January-December 2017
AQ
02/22PLEDPHARMA PUBL : Year-end Report January-December 2017
AQ
02/13SOLASIA PHARMA KK : PledOx shows favorable safety and tolerability profile in th..
AQ
02/09PLEDOX® SHOWS FAVORABLE SAFETY AND T : PledPharma AB (“PledPharma”) ..
AQ
02/08DELAYED DELIVERY OF STUDY DRUG FOR T : PledPharma AB, today announces a delay in..
AQ
2017PRINCIPAL INVESTIGATOR JAMES DEAR PR : PledPharma announces that an abstract pre..
AQ
2017PLEDPHARMA PUBL : First patient included in Phase I study aiming at supporting e..
AQ
More news
Financials ( SEK)
Sales 2018 6,00 M
EBIT 2018 -88,0 M
Net income 2018 -91,0 M
Finance 2018 230 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 93,9x
EV / Sales 2019 24,1x
Capitalization 793 M
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Nicklas Westerholm Chief Executive Officer
Håkan Åström Chairman
Jacques Näsström Chief Scientific Officer & Vice President
Stefan Carlsson Chief Medical Officer & VP-Clinical Development
Magnus Andreas Bunge Director
Sector and Competitors
1st jan.Capitalization (M$)
PLEDPHARMA AB (PUBL)91
GILEAD SCIENCES-5.60%88 197
VERTEX PHARMACEUTICALS4.24%39 825
REGENERON PHARMACEUTICALS-19.72%31 221
GENMAB19.78%11 932
BEIGENE LTD (ADR)97.99%10 364